Baxter International, Inc. (BAX)

NYSE: BAX · IEX Real-Time Price · USD
51.30
-1.92 (-3.61%)
At close: Dec 5, 2022 4:00 PM
50.99
-0.31 (-0.60%)
After-hours: Dec 5, 2022 4:05 PM EST
-3.61%
Market Cap 26.83B
Revenue (ttm) 14.74B
Net Income (ttm) -2.38B
Shares Out 504.00M
EPS (ttm) 2.00
PE Ratio 25.65
Forward PE 14.43
Dividend $1.15 (2.24%)
Ex-Dividend Date Dec 1, 2022
Volume 4,940,515
Open 52.78
Previous Close 53.22
Day's Range 51.13 - 52.98
52-Week Range 49.83 - 89.7
Beta 0.59
Analysts Buy
Price Target 65.01 (+26.7%)
Earnings Date Oct 27, 2022

About BAX

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical pro... [Read more]

Industry Health Care Equipment & Supplies
Founded 1931
CEO Jose Almeida
Employees 60,000
Stock Exchange NYSE
Ticker Symbol BAX
Full Company Profile

Financial Performance

In 2021, BAX's revenue was $12.78 billion, an increase of 9.52% compared to the previous year's $11.67 billion. Earnings were $1.28 billion, an increase of 16.52%.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for BAX stock is "Buy." The 12-month stock price forecast is 65.01, which is an increase of 26.73% from the latest price.

Price Target
$65.01
(26.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Baxter Introduces ExactaMix Pro, Next-Generation Automated Nutrition Compounder, at ASHP Meeting

DEERFIELD, Ill.--( BUSINESS WIRE )--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, announces the launch of the ExactaMix Pro Automated Compounder, which is expected to be av...

4 days ago - Business Wire

Baxter to Present at the 5th Annual Evercore ISI HealthCONx Conference

DEERFIELD, Ill.--( BUSINESS WIRE )--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022. Jay Sa...

2 weeks ago - Business Wire

6 Healthcare Stocks With Room to Climb

Zoetis and Medtronic are among the healthcare stocks with the most room to rise, according to Wall Street analysts' average price targets.

Other symbols: CNCCVSEWMDTZTS
2 weeks ago - Barrons

Baxter Declares Quarterly Dividend

DEERFIELD, Ill.--( BUSINESS WIRE )--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share o...

2 weeks ago - Business Wire

Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022

DEERFIELD, Ill., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations about the role inn...

3 weeks ago - GlobeNewsWire

Spectral Medical Inc. Closes $10.8 Million Public Offering and Concurrent Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

1 month ago - GlobeNewsWire

Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M

Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

1 month ago - Zacks Investment Research

Baxter International (BAX) Q3 Earnings Match Estimates

Baxter (BAX) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Block, RingCentral, and Other Stocks Facing Tax-Loss Selling

Some of the stocks that have suffered the most this year could get hit some more as investors sell them to create tax losses.

Other symbols: MTCHOLPXRNGSQ
1 month ago - Barrons

Baxter Reports Third-Quarter 2022 Results

DEERFIELD, Ill.

1 month ago - Business Wire

Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?

Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.

1 month ago - Zacks Investment Research

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

1 month ago - Zacks Investment Research

The Baxter International Foundation Announces $3 Million in New Grants to Organizations Working to Advance Racial Jus...

DEERFIELD, Ill.--(BUSINESS WIRE)--The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), announced today it will provide a combined $3 million in new racial ...

2 months ago - Business Wire

Should You Buy Baxter Stock Under $60?

Baxter stock (NYSE: BAX) has seen a 32% fall this year, underperforming the broader S&P500 index, down 17%.

2 months ago - Forbes

Baxter to Host Third-Quarter 2022 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2022 financial results on Thursday, October 27, ...

2 months ago - Business Wire

Baxter Expands Historically Black Colleges and Universities Partnerships, Funding Commitments to Further the Pipeline...

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reinforced its commitment to expand the pipeline of Black healthcare professionals through several ...

2 months ago - Business Wire

Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care

Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.

2 months ago - Zacks Investment Research

Two-Minute Drill: FedEx, Verizon & Baxter

Burns McKinney, NFJ Investment, joins ‘Closing Bell: Overtime' to give his take on FedEx, Verizon and Baxter.

Other symbols: FDXVZ
3 months ago - CNBC Television

Baxter Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearanc...

3 months ago - Business Wire

Baxter to Present at the 2022 Wells Fargo Healthcare Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. Jay Saccaro, ...

3 months ago - Business Wire

Baxter to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2...

3 months ago - Business Wire

Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M

Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

4 months ago - Zacks Investment Research

Why Baxter International Stock Is Tumbling Today

Investors weren't happy with the company's Q2 update.

4 months ago - The Motley Fool

Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates

Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research